Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00087672 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study of CC-5013 in Myelofibrosis
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
NCT00087672: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00087672 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 41 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00087672, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if CC-5013 (lenalidomide) can help to control myelofibrosis. The safety of lenalidomide in the treatment of myelofibrosis will also be studied.
Interventions
- DRUG CC-5013
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2004-07 |
| Est. Completion | 2009-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00087672
The ClinicalTrials.gov registry entry for NCT00087672 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CC-5013 is the first listed.
NCT00087672 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00087672 about?
NCT00087672 is a clinical study titled "A Phase II Study of CC-5013 in Myelofibrosis". The goal of this clinical research study is to learn if CC-5013 (lenalidomide) can help to control myelofibrosis. The safety of lenalidomide in the treatment of myelofibrosis will also be studied.
What is the current status of trial NCT00087672?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2004-07. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00087672?
The interventions under investigation include: CC-5013 (DRUG).
Who is sponsoring clinical trial NCT00087672?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.